

U.S. markets close in 2 hours 18 minutes

S&P 500 4,364.14 -78.97 (-1.78%)	Dow 30 34,361.90 -507.47 (-1.46%)	Nasdaq 14,601.21 -368.75 (-2.46%)	Russell 2000 2,245.53 -35.47 (-1.56%)	Crude Oil 75.17 -0.28 (-0.37%)	Gold 1,736.30 -15.70 (-0.90%)
--	---	---	---	--	---

CISION

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD



Tue, September 28, 2021, 6:00 AM · 3 min read

In this article:

GTSIF ☆
+36.96%

Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD

VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ - Lobe Sciences Ltd. ("**Lobe**" or the "**Company**") (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical research studies, in established rodent models of mild traumatic brain injury/concussion ("mTBI") and post-traumatic stress disorder ("PTSD"), using psilocybin plus N-Acetylcysteine ("NAC"). The study is being conducted in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the leadership of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

Quote Lookup

Related Quotes

Symbol	Last Price	Change	% Change
GTSIF	0.0504	+0.0136	+36.9565%
Lobe Sciences Ltd.			

Recently Viewed >

Symbol	Last Price	Change	% Change
MMED.NE	3.0300	-0.0400	-1.3029%
Mind Medicine (MindMed) Inc.			

TRENDING

1. U.S. FAA to deploy software to reduce airport delays
2. EXPLAINER-U.S. Appalachian gas pipeline projects go by the wayside
3. Mastercard jumps in buy now, pay later space in a big way
4. Democrats Debate Debt Limit Plan After Yellen's Oct. 18 Deadline



Lobe Sciences Ltd. Logo (CNW Group/Lobe Sciences Ltd.)

The rodents treated with the combination of psilocybin and NAC performed statistically significantly better ($P < 0.000005$) than the rodents treated with monotherapy with psilocybin, NAC or placebo.

Philip Young, CEO of Lobe stated, "I am thankful to Dr. Hoffer and his team for their excellent work. This data is validation of our therapeutic hypothesis that the use of these two active therapeutics provides superior efficacy to either placebo or single drug therapy in this model of TBI and PTSD. We believe that these data directly support our IP and will allow us to build on our leadership position in the rapidly evolving psychedelic therapeutics marketplace. Despite the significant shortage of psilocybin in North America the Miami team was able to deliver these data. However, the shortage has impacted the timing of the next planned studies. We have responded to this supply shortage by working to identify a manufacturing company who will supply high purity cGMP psilocybin to the University of Miami so that the remaining studies can be completed."

Dr. Hoffer stated "These are promising results that suggest that a combination of psilocybin and NAC can work better than either drug administered as a single agent after traumatic brain injury. We look forward to future work that will help to reaffirm these outcomes and further clarify the role of medical countermeasures in combatting traumatic insults to the brain."

Maghsoud Dariani, Chief Science Officer of Lobe said, "We are extremely pleased that the interim data from our preclinical studies validates our therapeutic hypothesis that NAC plus psilocybin would provide superior efficacy over either agent

used alone. NAC remains the only compound that has

successfully completed a human phase 1 equivalent trial in a



Given there are currently no approved medicinal treatments for mTBI and PTSD, we feel this data is supportive of our plans to advance into future human clinical trials which we hope will eventually lead to approved therapeutics for these unmet needs."

Trials Methodology And Results

Rodent models have been essential for revealing the normal and pathological processes that influence learning and memory. The University of Miami team has extensive experience and expertise in running these and other important models. In a standard model of normal behavior that assess the amount of time that rodents exhibit exploratory activity, rodents who underwent trauma and treated with the combination agents spent significantly more time exploring than they did with single agents or vehicle alone. The rodents treated with the combination of psilocybin and NAC performed statistically significantly better ($P < 0.000005$) than the rodents treated with monotherapy with psilocybin, NAC or placebo.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE NOT REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company; the development of effective delivery methods and commercialization potential of the nasal mist device; research and development using NAC and

Company's studies; anticipated timing and announcement of initiation of the first human study with Lobe's patent pending combination therapeutics of psilocybin and NAC (N-Acetylcysteine); statements and expected timing regarding cGMP psilocybin supply and availability; expected advancement into future human clinical trials; statements regarding future approved therapeutics; and the expected timing for the launch of new products and revenue-generating activities, are all forward looking statements that involve risks and uncertainties. Forward-looking statements, by their very nature, require management to make assumptions and are subject to inherent risks and uncertainties, and while management of the Company believes the forward-looking statements contained herein have a reasonable basis, the possibility exists that our predictions, forecasts, projections, expectations or conclusions will not prove to be accurate. Material assumptions that underlie the forward-looking statements included in this news release include, without limitation, assumptions regarding: the outcomes of scientific studies showing the efficacy of psychedelic therapies on mTBI and PTSD, increasing acceptance in the medical community and among consumers for psychedelic therapies as an effective treatment modality; the Company having access to sufficient capital needed to support its various objectives, expected synergies from M&A transactions and the timing of future studies, regulatory approvals and our ability to capitalize on business opportunities; the Company having availability and supply of high-purity cGMP psilocybin; and the impact of COVID-19 on our business plans. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. As a result of the inherent uncertainty of forward-looking statements, there can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements, whether as a result of known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. Important risks and uncertainties that could cause actual results to differ materially from the Company's expectations include without limitation risks

relating to: that we may not have the capital needed or will not be able to raise sufficient capital to support our business



scientific research; adverse changes to the regulatory environment in which we operate; regulatory delays or the failure to obtain required regulatory approvals; failure to capitalize on business opportunities and develop revenue-generating activities; contract counterparty risks; key personnel risk; business integration risks; risks inherent to equity and debt markets and their effects on our share price, and such other risks as may be detailed from time to time in the filings made by the Company pursuant to securities regulations, as well as other risks that may presently be unknown to us or which we consider to be immaterial at the time such forward-looking statements are made. As a result of these risks and uncertainties, the Company cannot guarantee that any forward-looking statement will materialize as expected, and the reader is therefore cautioned not to place undue reliance on any forward-looking statements contained in this news release. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement, are made only as of the date of this news release and the Company does not intend to update any of the forward-looking statements contained in this news release except as expressly required by applicable securities laws.

Cision

View original content to download


multimedia:<https://www.prnewswire.com/news-releases/lobe-sciences-announces-data-demonstrating-that-its-combination-therapeutic-candidates-are-significantly-more-effective-than-monotherapy-in-mtbi-and-ptsd-301386146.html>

SOURCE Lobe Sciences Ltd.



Popular in the Community

RECOMMENDED STORIES



Motley Fool

Is Cassava Sciences Back in the Game?

Last week, biotech Cassava Sciences (NASDAQ: SAVA) published topline interim-analysis data for simufilam, a potential treatment for Alzheimer's disease. Unfortunately, these developments do not paint a clear path to...

7h ago



Yahoo Finance

CDC 'starting to see mix-and-match data' for COVID-19 vaccines: Director

CDC Director Dr. Rochelle Walensky says the U.S. will soon have enough data to decide on mixing-and-matching COVID-19 vaccines and boosters.

4h ago



Ad • Interactive Brokers

Earn Extra Income with Stock Yield Enhancement

Our Stock Yield Enhancement Program is a simple, transparent way to earn supplemental income on your fully-paid shares. Open an IBKR account today!



Motley Fool

3 COVID Stocks Ready to Take On the Delta Variant

If the COVID mutation takes a turn for the worse, what stocks will protect your port? Our trio of Fools has three suggestions.

18h ago




Motley Fool

3 Biotech Stocks That Could Make You Filthy Rich

Biotech stocks have been some of the most reliable capital-appreciation vehicles in the entire market for the past two decades. As proof, biotech equities such as CRISPR Therapeutics, Moderna, Novavax, OcuGen, and...

1d ago





711 ago

Ad • Yale SOM Exec Ed

Tackle business problems

Discover how you can leverage social networks to build a future-orientated business.

...




Motley Fool

3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%

Here are three big pharma stocks that Wall Street thinks could soar by at least 30% within the next 12 months. The consensus Wall Street price target for Bristol Myers Squibb (NYSE: BMY) reflects a premium of nearly...

8h ago



TipRanks

Oppenheimer Says There's Room for Over 50% Gains in These 3 Stocks

There is an old Chinese curse that says "May he live in interesting times." Like it or not, we live in interesting times. COVID is receding but not gone, and while markets have rebounded well from the crisis (the S&P 500 is up...

2d ago



The Wall Street Journal

Merck Nears Deal to Acquire Acceleron Pharma

The deal for Acceleron, which has a market value of around \$11 billion, could be announced this week and bolster the pharmaceutical giant's rare-disease business.

18h ago

Anuncio • Graneodin

Prueba Graneodín F®

Con doble efecto: analgésico y antiinflamatorio en una sola pastilla.

...

MarketWatch

Hopes rise that Pfizer COVID-19 vaccine will be authorized for use in children aged 5 to 11 by late October, and Russia suffers

Pfizer and German partner BioNTech have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, raising hopes that a key patient group can...

2h ago

Zacks Small Cap Research

KTRA: 2Q:21 Update

By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT VAL-083 Phase II Topline Data (MD Anderson) - Adjuvant Arm Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced...

1d ago

Motley Fool

Why Altimmune Stock Is Under Pressure Today

Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.

2h ago

American City Business Journals

Walmart, Epic Systems partner to provide e-health records

Dr. Cheryl Pegus, EVP of Walmart Health & Wellness, is teaming with Epic CEO Judy Faulkner, one of the country's most successful self-made women.

4h ago

HuffPost Life

What Happens If You Mix COVID Vaccine Doses?

Can you get a Pfizer or Moderna booster if you initially got the other one? What about Johnson & Johnson? Here's what we know now.

20h ago

Eat This, Not That!

The One Thing You May Need to Grow Muscles As You Age, New Study Suggests

As you age, you naturally lose more and more of your muscle strength each year. It's a naturally occurring process that the body goes through, but a new study suggests that there may be a way to counteract this process. I...

22h ago

Ad • Codere



¡Lo azaroso y grandioso de la Ruleta!

En Codere contamos con los mejores juegos en español y por supuesto, las mejores ruletas. Disfrútala en nuestro casino online.

Reuters

Merck in advanced talks to buy Acceleron Pharma - WSJ

(Reporting by Uday Sampath and Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

20h ago

Motley Fool

Could AbbVie's New Collaboration Be a Blockbuster?

AbbVie recently announced a strategic partnership with Regenxbio for wet age-related macular degeneration and diabetic retinopathy treatment.

1d ago

Barrons.com

A Vaccine for Kids Is Closer as Pfizer Sends Trial Data to FDA

The company hasn't formally asked for an emergency-use authorization for the vaccine in children aged five to twelve, but plans to in coming weeks.

5h ago

Ad • Novelodge



Place A Bag On Your Car Mirror When Traveling

Brilliant Car Cleaning Hacks Local Dealers Wish You Didn't Know

Brockway/The Daily BeastNEW
DELHI—An onslaught of fatal...
1d ago

Reuters

New York hospitals fire, suspend staff who refuse COVID vaccine

New York hospitals on Monday began firing or suspending healthcare workers for defying a state order to get the COVID-19 vaccine, and resulting staff shortages prompted some hospitals to postpone elective...

1d ago

Benzinga

Psyched: Delic Buys 10 Ketamine Clinics For \$10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT

The Week In Psychedelics: Delic Signs \$10 Million Merger With Chain Of Ketamine Clinics Atai Subsidiary DemeRx Launches Phase 1/2a Clinical Trial On Ibogaine Small Pharma Completes Phase 1 Trial on DTM For Depressio...

1d ago

